• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

    18.20 -0.90 (-4.71%)
    Streaming Delayed Price Updated: 3:06 PM EDT, Jul 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Amneal Pharmaceuticals Q2 Earnings Call Highlights ↗
    Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at... 
    Via MarketBeat
    Topics Earnings
    Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
    Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ... 
    Via StockStory
    News headline image
    Amneal Reports Second Quarter 2026 Financial Results
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
    Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect. Amn... 
    Via StockStory
    News headline image
    Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
    Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    News headline image
    Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    3 Reasons AMRX is Risky and 1 Stock to Buy Instead
    Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The... 
    Via StockStory
    Topics Stocks
    News headline image
    Amneal to Report Second Quarter 2026 Results on July 30, 2026
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
    As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    1 Mooning Stock Worth Your Attention and 2 We Question
    Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
    Via StockStory
    News headline image
    1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
    Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
    Via StockStory
    News headline image
    3 Russell 2000 Stocks with Open Questions
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
    Via StockStory
    News headline image
    Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
    Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
    Via MarketBeat
    News headline image
    Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Why Amneal (AMRX) Stock Is Trading Up Today
    What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini... 
    Via StockStory
    News headline image
    Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    3 Profitable Stocks with Open Questions
    Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
    Via StockStory
    Topics Economy
    News headline image
    Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
    Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    2 Reasons AMRX is Risky and 1 Stock to Buy Instead
    Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ... 
    Via StockStory
    Topics Artificial Intelligence Stocks
    News headline image
    Amneal Reports First Quarter 2026 Financial Results
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗
    Amneal (AMRX) Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Amneal (AMRX) Q2 2025 Earnings Transcript ↗
    Amneal (AMRX) Q2 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Supply Chain
    News headline image
    1 Value Stock to Target This Week and 2 Facing Challenges
    Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
    Via StockStory
    News headline image
    Amneal (AMRX) Q1 2026 Earnings Transcript ↗
    Amneal (AMRX) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Amneal (AMRX) Q1 Earnings Report Preview: What To Look For
    Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ... 
    Via StockStory
    News headline image
    Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
    From Kashiv BioSciences, LLC
    Via Business Wire
    News headline image
    Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.